Boston Scientific device outperforms warfarin in atrial fibrillation study

05/10/2013 | MassDevice.com (Boston)

Boston Scientific's Watchman device proved more effective and safer in treating patients with atrial fibrillation than the anti-coagulant drug warfarin, according to a 707-participant study. The study showed Watchman was superior to warfarin "for the combined endpoint of all stroke, cardiovascular or unexplained death and systemic embolism," the company said in a release.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC